Loading briefing details...
News Abstract
By: NewsAbstract Editorial Team
Topic: Arts & Media
March 19, 2026
This announcement positions Fortitude Filmworks as a significant player in premium scripted television, launching a series that deeply engages with critical contemporary themes like AI and human augmentation. <em>Bio Cross</em> offers a culturally relevant narrative, signaling a commitment to high-value, scalable intellectual property and diverse talent, shaping the future of genre storytelling.
DALLAS, TX – March 19, 2026 – Fortitude Filmworks today officially announced the lead cast for its highly anticipated sci-fi drama series, Bio Cross (formerly SAM). This groundbreaking project is set to redefine storytelling at the intersection of biotechnology, identity, and power, signaling the company’s bold expansion into premium scripted content. Bio Cross is a flagship intellectual property designed for global audiences.
The series features Jordan Bryant as Sam Logan, a complex lead navigating a future shaped by advanced human augmentation and scientific experimentation. Opposite Bryant, Florida Plamore stars as Dr. Jakob Cross, a visionary yet morally ambiguous scientist whose groundbreaking work drives the central conflict. The dynamic ensemble, including Jamaal Randall, Abyon Ausar, Joseph Mason, and Brandon DeSpain, adds significant depth to the narrative’s psychological intensity and ethical dilemmas.
Bio Cross arrives at a crucial cultural moment, as discussions around AI, bioengineering, and human augmentation intensify. Fortitude Filmworks is developing this high-concept, character-driven drama with long-term franchise potential, aiming to resonate with audiences seeking elevated genre storytelling rooted in contemporary societal themes. This project marks a key milestone in the company’s strategic expansion into high-value content and original IP ownership.